NuvOx Therapeutics key facts
- Developer of a pharmaceutical company designed to treat life-threatening diseases.
- It has raised $19.8M across 1 recorded rounds; the latest was Debt ($1.1M) in Jan 2023.
- Notable investors include National Institutes of Health, Keiretsu Forum, Band of Angels, Arizona Commerce Authority, Arizona Tech Investors — 19 tracked in total.
- NuvOx Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently Nov 2024 ($235K sold to 4 investors).
- Status: Privately Held (backing).
Who backs NuvOx Therapeutics
19+- ·The complete investor list: 19 names
- ·Watch NuvOx Therapeutics: the Monday email on marks, rounds and moves
NuvOx Therapeutics funding rounds
1 roundsHow much has NuvOx Therapeutics raised?
NuvOx Therapeutics has raised $19.8 million in total; 1 of its rounds is on record. The largest on record was a $1.1 million debt round in Jan 2023.
NuvOx Therapeutics has filed 2 Form Ds with the SEC since 2023, most recently in Nov 2024 ($235,000 sold to 4 investors).
NuvOx Therapeutics investors
19 investors are on record for NuvOx Therapeutics, including National Institutes of Health, Keiretsu Forum, Band of Angels and Arizona Commerce Authority. The debt round in Jan 2023 drew 2 investors.
About NuvOx Therapeutics
Developer of a pharmaceutical company designed to treat life-threatening diseases. The company's platform develops a drug that reverses hypoxia by increasing the amount of oxygen carried in the body and improves the flow of oxygen from the lungs to the blood and from blood to tissue, enabling medical practitioners to improve oxygen delivery in the bloodstream to help treat life-threatening conditions.
- Sector
- Healthcare
- HQ
- Tucson, AZ, United States
- Founded
- 2008
- Employees
- 13
- Website
- nuvoxtherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
NuvOx Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.